PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Highlights Beta-Amyloid 1-42 Peptides - AnaSpec, EGT Group is one of the world's most trusted sources of integrated proteomic solutions specifically designed for Alzheimer's Disease research - AnaSpec.com
AnaSpec Highlights Beta-Amyloid 1-42 Peptides

 

NewswireToday - /newswire/ - Fremont, CA, United States, 2012/06/27 - AnaSpec, EGT Group is one of the world's most trusted sources of integrated proteomic solutions specifically designed for Alzheimer's Disease research - AnaSpec.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Our large collection of ß-Amyloid (1-42) peptides includes:

Native sequences – human and mouse/rat sequences (unless otherwise specified, sequences are human in origin)
Single or multiple amino acid substitution sequences, e.g. S26C
Biotin labeled sequences – N or C terminally labeled, with or without linker
Dye labeled sequences – HiLyte Fluor™ or classic dye labeled
ClearPoint™ heavy-isotope labeled sequences
Shorter sequences that end on the 42nd amino acid and analog
HFIP treated β-Amyloid (1-42)
ß-Amyloid (Aß) peptides are generated as cleavage products 39 to 43 amino acids in length from the membrane protein, Amyloid Precursor Protein (APP) by two proteases, β-secretase and γ-secretase.1-3 While only a small amount is processed by β-Secretase, also known as BACE1 (β-secretase APP cleaving enzyme) or memapsin, APP is predominantly processed by α-Secretase, producing a 83-amino acid C-terminal fragment, C83. Subsequent cleavage of C83 by γ-secretase produces a non-toxic N-terminal 3kD protein.1-2
Aßs are amphiphilic peptides with a hydrophilic N-terminal domain (residues 1 to 28) and a hydrophobic C-terminal (residues 29 to 40-42), the latter corresponding to a part of the transmembrane domain of APP.4 β-Amyloid assembly into fibrils is initiated by a conformational transition from random coil to β-sheet (hence the name β-amyloid) and a nucleation-dependent aggregation process.4 Aβ peptides that are 39 to 42 amino acid residues in length with a molecular mass of approximately 4 kDa are the core components of neuritic plaques seen in Alzheimer’s disease (AD) brains. The presence of excess amount of Aß deposits and neurofibrillary tangles, NFTs, 5-6 comprising of hyperphosphorylated Tau proteins are the hallmarks of an AD brain.1
Aβ (1-42), a major component of amyloid plaques, accumulates in neurons of Alzheimer’s disease (AD) brains. Biochemical analysis of the amyloid peptides isolated from AD brain indicates that Aβ (1-42) is the principal species associated with senile plaque amyloids, while Aβ (1-40) is more abundant in cerebrovascular amyloid deposit.7-8

References:

1. Selkoe DJ. Nature 399, A23 (1999).
2. Suh, Y-H. and F. Checler, Pharmacol Rev 54, 469 (2002).
3. Kang, J. et al. Nature 325, 733 (1987).
4. Jarrett, JT. et al. Biochem 32, 4693 (1993).
5. Masters, CL. et al. EMBO J 4, 2757 (1985).
6. Braak, H. et al. Acta Neuropathol 87, 554 (1994).
7. Nagele, R. et al. Neurosci 110, 199 (2002).
8. Garzon-Rodriguez, W. et al. J Biol Chem 272, 21037 (1997).

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Highlights Beta-Amyloid 1-42 Peptides

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tiffany Kao - AnaSpec.com 
510-791-9560
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  MagLar, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)